Exonate successfully completes their Phase Ib/IIa trial for diabetic macular oedema

Exciting achievement for portfolio company Exonate who have successfully completed their phase Ib/IIa clinical trial for their lead candidate EXN407, the first topical treatment for diabetic macular edema. In collaboration with The Janssen Pharmaceutical Companies of Johnson & Johnson, EXN407 delivered promising outcomes, not only meeting all safety and pharmacokinetics requirements, but also demonstrating encouraging biological activity.

To read more on this announcement, head to https://rb.gy/rliwdi